EBR Systems Inc (ASX: EBR) Share Price and News

Price

$1.165

Movement

0.055 (+4.96%)

as at 6 Jun - Closed (20 mins delayed)

52 Week Range

$0.82 - $2.08

 
1 Year Return

+4.35%

EBR Systems Inc Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $499.90 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 373.08 million
Earnings per share -0.130
Dividend per share N/A
Year To Date Return 8.29%
Earnings Yield N/A
Franking -
Share Price

$1.165

Day Change

0.055 (+4.96%)

52 Week Range

$0.82 - $2.08

Yesterday's Close

$1.11

Today's Open

$1.18

Days Range

$1.135 - $1.215

Volume

1,822,545

Avg. Volume (1 month)

1,001,885

Turnover

$2,139,869

as at 6 Jun - Closed

  • EBR Systems Inc (ASX: EBR)
    Latest News

    Lines of codes and graphs in the background with woman looking at laptop trying to understand the data.
    Share Fallers

    Why Computershare, EBR Systems, Inghams, and Myer shares are falling today

    These shares are ending the week in the red. But why?

    Read more »

    A man holds his head in his hands, despairing at the bad result he's reading on his computer.
    Healthcare Shares

    Why is this ASX All Ords stock sinking 14% on Friday?

    Let's see why investors hitting the sell button today.

    Read more »

    Kid putting a coin in a piggy bank.
    Small Cap Shares

    'Plenty of upside': 2 ASX small-cap shares to buy while they're cheap

    One of these stocks has doubled since the start of the year. See what one expert is recommending to add…

    Read more »

    Three guys in shirts and ties give the thumbs down.
    Share Fallers

    Why Collins Foods, EBR, Gold Road, and Woodside shares are dropping today

    These ASX shares are ending the week deep in the red.

    Read more »

    a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
    Share Gainers

    Why Bigtincan, EBR, Gentrack, and New Hope shares are storming higher

    These ASX shares are having a strong start to the week.

    Read more »

    a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
    Healthcare Shares

    Do ASX biotech shares offer 'good buying' after the sell-off? Experts weigh in

    After some strong support in early 2021, biotechnology stocks took a beating over the past 6 months.

    Read more »

    EBR ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About EBR Systems Inc

    EBR Systems Inc is engaged in treatment for patients suffering from cardiac rhythm diseases by developing therapies using wireless cardiac stimulation. The company's Wise CRT System uses proprietary wireless technology to deliver pacing stimulation directly inside the left ventricle of the heart. It conducts its operations in the United States.

    EBR Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    06 Jun 2025 $1.17 $0.05 4.50% 1,822,545 $1.18 $1.22 $1.14
    05 Jun 2025 $1.11 $0.02 1.83% 834,249 $1.09 $1.14 $1.09
    04 Jun 2025 $1.09 $-0.01 -0.90% 1,011,054 $1.10 $1.11 $1.09
    03 Jun 2025 $1.11 $0.02 1.84% 618,825 $1.09 $1.11 $1.08
    02 Jun 2025 $1.09 $-0.03 -2.70% 685,783 $1.11 $1.12 $1.08
    30 May 2025 $1.11 $0.00 0.00% 1,497,642 $1.09 $1.13 $1.07
    29 May 2025 $1.11 $0.01 0.90% 1,402,788 $1.12 $1.15 $1.08
    28 May 2025 $1.11 $-0.04 -3.48% 3,328,811 $1.15 $1.15 $1.09
    27 May 2025 $1.15 $-0.04 -3.36% 1,771,085 $1.18 $1.18 $1.09
    26 May 2025 $1.19 $-0.02 -1.65% 1,073,984 $1.15 $1.26 $1.13
    23 May 2025 $1.21 $0.09 8.04% 1,958,325 $1.13 $1.23 $1.13
    22 May 2025 $1.12 $-0.10 -8.23% 2,759,917 $1.10 $1.19 $1.04
    20 May 2025 $1.22 $0.05 4.27% 679,131 $1.20 $1.25 $1.18
    19 May 2025 $1.17 $0.06 5.41% 363,739 $1.12 $1.17 $1.10
    16 May 2025 $1.11 $0.02 1.83% 359,415 $1.09 $1.13 $1.09
    15 May 2025 $1.09 $-0.04 -3.54% 394,382 $1.13 $1.14 $1.08
    14 May 2025 $1.13 $-0.05 -4.24% 477,579 $1.19 $1.19 $1.12
    13 May 2025 $1.18 $0.12 11.27% 732,591 $1.07 $1.18 $1.07
    12 May 2025 $1.07 $-0.07 -6.17% 887,691 $1.16 $1.16 $1.06
    09 May 2025 $1.14 $-0.04 -3.39% 476,986 $1.16 $1.18 $1.12
    08 May 2025 $1.18 $-0.01 -0.84% 475,813 $1.18 $1.19 $1.14

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    22 May 2025 Christopher Nave Issued 175,781 $196,874
    Issue of options.
    22 May 2025 Karen Drexler Issued 175,781 $196,874
    Issue of options.
    22 May 2025 Allan Will Issued 214,844 $240,625
    Issue of options.
    22 May 2025 Bronwyn Evans Issued 175,781 $196,874
    Issue of options.
    22 May 2025 David Steinhaus Issued 175,781 $196,874
    Issue of options.
    22 May 2025 John McCutcheon Issued 1,884,615 $2,110,768
    Issue of options.
    22 May 2025 Trevor Moody Issued 175,781 $196,874
    Issue of options.
    31 Dec 2024 Allan Will Buy 110,000 $15,400
    Exercise of options. US$
    31 Dec 2024 Allan Will Exercise 110,000 $15,400
    Exercise of options. US$
    26 Nov 2024 Bronwyn Evans Issued 150,000 $66,000
    Exercise of options.
    26 Nov 2024 Bronwyn Evans Exercise 150,000 $66,000
    Exercise of options.
    16 Oct 2024 Bronwyn Evans Issued 8,370 $6,863
    Rights issue.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Christopher Dean Nave Non-Executive Director Oct 2017
    Dr Nave is a Founder and Managing Director of Brandon Capital Partners and the CEO of the Brandon BioCatalyst Fund. Dr Nave previously served as the Director of Commercialisation at the Baker Heart Research Institute and Alfred Hospital. Dr Nave is currently a director of The Australian Investment Council, and the following privately held companies; Azura Ophthalmics, Inc., Certa Therapeutics Pty Ltd., Global Kinetics Corporation Ltd., PolyActiva Pty Ltd., and Pathios Plc.
    Ms Karen Ruth Drexler Non-Executive Director Oct 2021
    Ms Drexler is a serial entrepreneur with expertise in the fields of digital health, medical devices, and diagnostics. Currently serving on the boards of two other public companies, ResMed, Inc. (NYSE: RMD), a leader in connected medical devices and out of hospital software, where she chairs the compensation committee and serves on the nominating and governance committee, and Outset Medical Inc. (Nasdaq: OM), a Medtech company innovating dialysis treatment, where she is a member of both the compensation and nomination and governance committees. Ms Drexler also serves on the boards of two private companies: VIDA Diagnostics Inc. and Huma.ai. She also acts as a senior strategic advisor for other early-stage companies and spent 11 years on the board of the Keller Center for Innovation in Engineering Education at Princeton University. Ms Drexler has operating experience including as CEO of Amira Medical (sold to Roche Diagnostics) and Sandstone Diagnostics (sold to LabCorp.) Ms Drexler is an active mentor and advisor to Astia, a global nonprofit that supports high-potential female founders, as well as a mentor for StartX, the Stanford University incubator.
    Mr Allan Roger Will Executive ChairmanExecutive Director May 2003
    Mr Will served as our Chairman, President and Chief Executive Officer from October 2011 until June 2019 and has served in the role of Executive Chair since June 2019. Mr Will is an executive with experience founding, funding, operating, and selling medical device companies. Mr Will also serves as Chair of the board of Fractyl Health, Inc., (Nasdaq: GUTS) a metabolic therapeutics company between August 2012 August 2024. Since 2014, he has served as a director of Fogarty Innovation, a not-for-profit organisation dedicated to advancing human health worldwide. Prior to these roles, Mr Will served as founding Managing Director of Split Rock Partners' (and its predecessor, St. Paul Venture Capital's) Silicon Valley venture capital office, focusing on the therapeutic medical device field. Previously, Mr Will founded The Foundry, an incubator dedicated to transforming medical device concepts into companies, where he also served as Chair and Chief Executive Officer from 1998 to 2002 and Chair until 2010, co-founding eleven companies including, among others, Ardian, Inc., a medical device company focused on treating hypertension, which was subsequently acquired by Medtronic plc, and Evalve Inc., a company treating heart failure by repairing mitral valves percutaneously, now a wholly owned subsidiary of Abbott Laboratories.
    Dr Bronwyn Joy Evans Non-Executive Director Oct 2021
    Dr Evans is a CEO with a technical background across multiple industry sectors including medical technology, manufacturing and technical regulation and standards. Dr Evans is currently the Chair of Building 4.0 CRC, the Chair ACOR Consultants and a Director at GME Pty Ltd. She has previously held CEO roles at Engineers Australia and Standards Australia and led innovation initiatives, including as Chair of the Industry Growth Center for Medical Technologies and Pharmaceuticals (MTPConnect). She has also held various senior executive roles, including at Cochlear and GE Healthcare.
    Dr David Mark Steinhaus Non-Executive Director Oct 2021
    Dr Steinhaus retired in 2019 as Vice President and General Manager of the Heart Failure Business for the Cardiac Rhythm and Heart Failure Division at Medtronic plc. Dr Steinhaus joined Medtronic in 2005, after 20 years of cardiology (electrophysiology) practice. In his initial capacity as Medical Director, Dr Steinhaus' responsibilities at Medtronic included bringing the physician voice to CRHF, identifying future opportunities in new product development, and serving as a liaison to government agencies, professional societies and medical groups. Subsequently, he took on more managerial roles including strategy, business development, R&D, and ultimately general manager of the Heart Failure Business. Closely associated with research and academia, performing clinical studies in implantable cardiac devices and leads, he served as Chair of the Department of Cardiology, and Director of the Electrophysiology Department at the Mid America Heart Institute and St. Luke's Hospital and Director of the Electrophysiology Fellowship Program at the University of Missouri at Kansas City School of Medicine. Since leaving Medtronic, he has served as a consultant and board member to multiple established and early-stage medical device companies.
    Mr John Graham McCutcheon Chief Executive OfficerPresidentExecutive Director Jun 2019
    Mr McCutcheon has 40 years of sales, marketing, and general management experience in medical devices. Mr McCutcheon started his career at American Hospital Supply (acquired by Baxter International) followed by DVI (acquired by Eli Lily), Perclose (acquired by Abbott Laboratories), Emphasys Medical (acquired by Pulmonx), Ventus Medical and Ceterix Orthopaedics (acquired by Smith & Nephew). Mr McCutcheon has also served on numerous boards of private companies in the medical device industry.
    Mr Trevor John Moody Non-Executive Director Oct 2017
    Mr Moody has also served since January 2010 as President of TM Strategic Advisors LLC, a management consultancy. Mr Moody was previously a General Partner at Frazier Healthcare Ventures, a large U.S. based private equity and venture capital firm, and ElectroCore (Nasdaq: ECOR), a U.S. based commercial stage bioelectronic medicine and wellness company, from April 2013 through August 2023. Mr Moody is currently a Director of Cardiac Dimensions Pty Ltd., Renew Medical Pty Ltd., and The Brain Protection Company Pty Ltd. Mr Moody was a Director of Simplify Medical Pty Ltd. at the time of its sale to NuVasive.
    Mr Brendan Case Company Secretary
    -
    Erik Strandberg Chief Commercial Officer
    -
    Gary William Doherty Chief Financial Officer
    -
    Spencer H Kubo Chief Medical Officer
    -
    Michael Hendricksen Chief Operating Officer
    -
    Pharoah Garma Chief Regulatory Officer
    -
    N Parker Willis Chief Technology Officer
    -
    Brendan Case Company Secretary
    -
    Allan Roger Will Executive Chair
    -
    John Graham McCutcheon President CEO and director
    -
    Andrew Shute Senior Vice President (Business Development)
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Split Rock Partners LP 19,732,458 5.29%
    J P Morgan Nominees Australia Pty Limited 19,053,784 5.11%
    MRCF3 Services (H) Pty Ltd <MRCF3 (H) A/C> 18,480,532 4.96%
    MRCF3 Services (HP) Pty Ltd <MRCF3 (HP) A/C> 16,823,969 4.51%
    Carnegie Innovation Fund No 2 LP 14,162,839 3.80%
    Argo Investments Limited 13,638,837 3.66%
    CHV III LP 12,818,782 3.44%
    MRCF3 Services (HP) Pty Ltd <MRCF3 (HP) A/C> i 10,203,745 2.74%
    UBS Nominees Pty Ltd 9,738,601 2.61%
    Citicorp Nominees Pty Limited 9,516,767 2.55%
    MRCF3 Services Pty Ltd <MRCF3 (AS) A/C> 8,782,983 2.36%
    Carnegie Healthcare Fund LP 8,776,909 2.35%
    HSBC Custody Nominees (Australia) Limited 8,262,471 2.22%
    BB6 Services (HP) CoInvestment Trusco Pty Ltd <BCP (HP) C-oInvestment A/C> 7,868,138 2.11%
    Mr Christopher John Pike & Ms Natalie Kay Green <The Pike Family A/C> 7,000,000 1.88%
    SPVC VI LLC 6,996,473 1.88%
    MHC Fund Services B Pty Ltd <MHC HOSTPLUS Co-Invt A/C> 6,615,306 1.77%
    Carnegie Venture Captial Pty Ltd <Carnegie Healthcare F/LP A/C> 6,175,754 1.66%
    MRCF3 Services (SW) Pty Ltd <MRCF3 (SW) A/C> 6,161,947 1.65%
    MRCF5 Services (TS) Pty Ltd <MRCF5 (TS) A/C> 6,111,111 1.62%

    Profile

    since

    Note